Is Mounjaro or Wegovy covered by the PBS in Australia?

Australia treats Ozempic, Wegovy and Mounjaro as three separate PBS questions, each at a different, unresolved stage as of September 2026. Ozempic has been PBS-subsidised for type 2 diabetes since 2020 — settled. Wegovy cleared its own advisory committee's recommendation for a narrow obesity-plus-heart-disease group in November 2025, but a year on, price negotiations are still unresolved and no listing date has been set. Mounjaro went further and then further still: the government's own Pharmaceutical Benefits Advisory Committee (PBAC) finally recommended subsidising it for type 2 diabetes in March 2026, after three earlier knockbacks — only for manufacturer Eli Lilly to announce weeks later that it wouldn't proceed with the listing at all, over price, leaving an estimated 450,000 Australians with inadequately controlled diabetes still paying full price for a drug their own government's advisers had just said should be subsidised.

The short version

Semaglutide (sold in Australia as Ozempic at the diabetes dose, and separately as Wegovy at the higher obesity dose) and tirzepatide (Mounjaro, approved under one brand for both indications) are all TGA-approved prescription medicines. Whether the Pharmaceutical Benefits Scheme (PBS) actually subsidises any given one of them is a separate question, decided drug-by-drug and indication-by-indication by the Pharmaceutical Benefits Advisory Committee (PBAC) and a subsequent price negotiation with the Department of Health, Disability and Ageing — and, unusually among the countries this site covers, a positive PBAC recommendation in Australia still leaves the manufacturer free to walk away from the deal rather than accept the government's price. That's exactly what happened to Mounjaro's diabetes bid in 2026, and it's the reason this page exists as a standalone story rather than a line in this site's EU reimbursement comparison.

What's already covered: Ozempic for diabetes since 2020

Ozempic (semaglutide) has been PBS-listed for type 2 diabetes since 1 July 2020, when it was added as a new treatment option alongside the existing GLP-1 class. Eligibility runs through the ordinary PBS authority process: a confirmed type 2 diabetes diagnosis, a documented trial of metformin first unless it's contraindicated, and HbA1c remaining above target on existing therapy, prescribed by a GP or endocrinologist. Without the subsidy a course would cost well over $1,700; with it, patients pay the standard PBS co-payment (around $41 per script, or about $6.60 with a concession card). None of the Wegovy or Mounjaro developments below change this — Ozempic's diabetes listing is unaffected either way, and it remains the one part of Australia's GLP-1 coverage picture that isn't currently in dispute.

Wegovy for obesity: recommended, but still unfunded a year later

On 6 March 2025, Health Minister Mark Butler formally asked the PBAC for its advice on equitable access to GLP-1 receptor agonist obesity treatments through the PBS — a deliberately broad brief, not a single-drug submission. Public consultation drew 540 submissions, most from people who had already used one of these drugs privately and who told the committee cost was the main barrier to continuing. The PBAC delivered that advice at its November 2025 meeting: it named several priority groups for earlier access — people with established cardiovascular disease, Aboriginal and Torres Strait Islander patients with obesity-related comorbidities, people with syndromic or medication-induced obesity, and people who need to lose weight to qualify for surgery — and separately recommended a specific, authority-required PBS listing for Wegovy itself, limited to adults with obesity and established cardiovascular disease (a prior heart attack, stroke, or symptomatic peripheral arterial disease) and a BMI of 35 or higher, or 32.5 or higher for patients of Aboriginal, Torres Strait Islander, or Asian ethnicity. The committee also advised a deliberately slow, managed rollout rather than an immediate broad listing, citing uncertainty about long-term outcomes and the risk of "leakage" beyond the intended population, and recommended against making the subsidy conditional on enrolling in wraparound allied-health programs, reasoning that would itself create a barrier for the patients it's meant to help.

Minister Butler publicly backed proceeding with a listing along those lines in January 2026. As of this review, more than a year after Wegovy first went on sale in Australia, the government and Novo Nordisk are still negotiating the confidential price and listing terms that a PBAC recommendation requires before anything reaches the PBS schedule — industry reporting has floated late 2026 or early 2027 as a plausible listing window, but no date has been confirmed. In the meantime, more than 400,000 Australians are estimated to already be paying the full private price for a GLP-1 drug, on the order of $4,000–$5,000 a year for one alone.

Mounjaro for diabetes: the advisers said yes, the manufacturer said no

Tirzepatide's own path through the PBAC for its type 2 diabetes indication took four meetings across nearly three years, and ended somewhere Wegovy's hasn't (yet) gone. The PBAC rejected it outright at its July 2023 meeting, rejected a revised resubmission again in November 2024, deferred a decision at its July 2025 meeting pending further changes, and finally recommended listing Mounjaro for adults with inadequately controlled type 2 diabetes at its March 2026 meeting — the committee's own published outcome cited real benefits (improved daily glucose readings, lower HbA1c, and weight loss) while also flagging the drug's high cost as a genuine access barrier for patients even with a positive recommendation on the table.

That barrier turned out to be the whole story. Within roughly two hours of the PBAC publishing its March-meeting outcomes, Eli Lilly Australia announced it would not proceed with the listing at all. The company said the price the government was willing to pay was "unrealistic and unviable" and lower than any comparable healthcare system's price for the drug worldwide, including China's, and that the recommendation's funding caps would have assigned Lilly a disproportionate share of the financial risk if use exceeded the government's budget assumptions. Lilly framed the decision as the end of "four reimbursement submissions and extensive departmental engagement over three years" without a workable outcome — not a rejection of the drug's value, but a refusal of the specific commercial terms attached to this recommendation. Medicines Australia chief executive Liz de Somer called the outcome "very disappointing" and pointed to it as evidence of a broader breakdown in how Australia negotiates PBS listings with manufacturers, rather than a dispute unique to this one drug. By Eli Lilly's own count, an estimated 450,000 Australians with inadequately controlled type 2 diabetes remained without subsidised access to Mounjaro as a direct result.

The story hadn't closed as of this review. In August 2026, Eli Lilly's global CEO, David Ricks, told Australian media the company was still open to reaching a deal and would consider "adaptive schemes" for pricing, but that any agreement ultimately came down to "the value placed on the medicine" — signalling continued, but still unresolved, talks rather than a final no.

Why this keeps happening

Australia's PBS process separates two decisions that other systems sometimes fold together: the PBAC assesses whether a drug is cost-effective enough to recommend for public subsidy at all, and only after a positive recommendation does the Department of Health negotiate the actual confidential price and any funding caps with the manufacturer. A positive PBAC recommendation is necessary to get a drug onto the PBS, but it isn't sufficient — the manufacturer can, and in Mounjaro's case did, decline the resulting commercial terms and walk away even after "winning" the recommendation stage. That's a structurally different failure point from the ones this site has documented elsewhere: Canada's own federal drug agency recommended reimbursing Wegovy in July 2025, and price negotiations between Canada's pan-Canadian Pharmaceutical Alliance and Novo Nordisk collapsed in December 2025 with no counter-offer ever exchanged — the same recommendation-then-collapse pattern now visible in Australia's Mounjaro case, in a different country against a different manufacturer.

What this doesn't change

None of the above affects whether these drugs are legal or available in Australia — Ozempic, Wegovy and Mounjaro are all TGA-approved prescription medicines, and a doctor can still prescribe any of them privately; the dispute is only over who pays what share of the cost. It also doesn't touch this site's separate page on Australia's 2024 compounding ban and TGA enforcement actions, which covers a different question entirely — who's allowed to make these medicines, not who subsidises the approved branded product. See Semaglutide and Tirzepatide for the underlying drugs' evidence and approval history, including how the UK's NHS and the EU's individual reimbursement systems ration or fund the same drugs on their own, different terms.